ES2780650T3 - Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer - Google Patents
Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2780650T3 ES2780650T3 ES16791420T ES16791420T ES2780650T3 ES 2780650 T3 ES2780650 T3 ES 2780650T3 ES 16791420 T ES16791420 T ES 16791420T ES 16791420 T ES16791420 T ES 16791420T ES 2780650 T3 ES2780650 T3 ES 2780650T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- compound
- formula
- pharmaceutically acceptable
- pyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JODQIWFFKDQLJG-SSDOTTSWSA-N CC(C)(C)OC(N1S(O)(O)OC[C@H]1COC)=O Chemical compound CC(C)(C)OC(N1S(O)(O)OC[C@H]1COC)=O JODQIWFFKDQLJG-SSDOTTSWSA-N 0.000 description 1
- AIVYLYCLCDWKEU-RWNHWRGESA-N CC(C)(C)OC(N1[S+](O)OC[C@@H]1COC)=O Chemical compound CC(C)(C)OC(N1[S+](O)OC[C@@H]1COC)=O AIVYLYCLCDWKEU-RWNHWRGESA-N 0.000 description 1
- UFVXAJVQXHAGDA-UHFFFAOYSA-N CCOC(c1nc(-c2ccnc(Cl)n2)c[nH]1)=O Chemical compound CCOC(c1nc(-c2ccnc(Cl)n2)c[nH]1)=O UFVXAJVQXHAGDA-UHFFFAOYSA-N 0.000 description 1
- KKBUAKLLEWKSNE-LBPRGKRZSA-N CCOC(c1nc(-c2nc(Cl)ncc2C)c[n]1C[C@H](C)NCc1cc(C(F)(F)F)ncn1)=O Chemical compound CCOC(c1nc(-c2nc(Cl)ncc2C)c[n]1C[C@H](C)NCc1cc(C(F)(F)F)ncn1)=O KKBUAKLLEWKSNE-LBPRGKRZSA-N 0.000 description 1
- SCTSUDKWBUYKGM-LBPRGKRZSA-N CCOC(c1nc(-c2nc(Cl)ncc2C)c[n]1C[C@H](C)NCc1nc(C(F)(F)F)ncc1)=O Chemical compound CCOC(c1nc(-c2nc(Cl)ncc2C)c[n]1C[C@H](C)NCc1nc(C(F)(F)F)ncc1)=O SCTSUDKWBUYKGM-LBPRGKRZSA-N 0.000 description 1
- SJNDZZROBMMJHR-UHFFFAOYSA-N CCOC(c1nc(-c2nc(Cl)ncc2Cl)c[n]1COCC[Si+](C)(C)C)=O Chemical compound CCOC(c1nc(-c2nc(Cl)ncc2Cl)c[n]1COCC[Si+](C)(C)C)=O SJNDZZROBMMJHR-UHFFFAOYSA-N 0.000 description 1
- GSJWTBPXHPDMHL-JTQLQIEISA-N CCOC(c1nc(-c2nc(Cl)ncc2Cl)c[n]1C[C@H](C)N(C(OC(C)(C)C)=O)S(O)(=O)=O)=O Chemical compound CCOC(c1nc(-c2nc(Cl)ncc2Cl)c[n]1C[C@H](C)N(C(OC(C)(C)C)=O)S(O)(=O)=O)=O GSJWTBPXHPDMHL-JTQLQIEISA-N 0.000 description 1
- MFXVDDUSPPQUJQ-AWEZNQCLSA-N C[C@@H](C[n]1c2nc(-c(nc(Nc3ccn[n]3C)nc3)c3Cl)c1)N(Cc1cccc(C)n1)C2=O Chemical compound C[C@@H](C[n]1c2nc(-c(nc(Nc3ccn[n]3C)nc3)c3Cl)c1)N(Cc1cccc(C)n1)C2=O MFXVDDUSPPQUJQ-AWEZNQCLSA-N 0.000 description 1
- CHIZSKFEQQPYIG-HNNXBMFYSA-N C[C@@H](C[n]1c2nc(-c3c(C)cnc(Nc4ccn[n]4C)n3)c1)N(Cc(cc1)cc(OC)c1F)C2=O Chemical compound C[C@@H](C[n]1c2nc(-c3c(C)cnc(Nc4ccn[n]4C)n3)c1)N(Cc(cc1)cc(OC)c1F)C2=O CHIZSKFEQQPYIG-HNNXBMFYSA-N 0.000 description 1
- VTWRYQNQNQTDJU-INIZCTEOSA-N C[C@@H](C[n]1c2nc(-c3c(C)cnc(Nc4ccn[n]4C)n3)c1)N(Cc1cccc(OC)c1)C2=O Chemical compound C[C@@H](C[n]1c2nc(-c3c(C)cnc(Nc4ccn[n]4C)n3)c1)N(Cc1cccc(OC)c1)C2=O VTWRYQNQNQTDJU-INIZCTEOSA-N 0.000 description 1
- OWPHFRAKUXEJOP-JTQLQIEISA-N C[C@@H](C[n]1c2nc(-c3nc(Cl)ncc3)c1)N(Cc(cc1)cc(F)c1F)C2=O Chemical compound C[C@@H](C[n]1c2nc(-c3nc(Cl)ncc3)c1)N(Cc(cc1)cc(F)c1F)C2=O OWPHFRAKUXEJOP-JTQLQIEISA-N 0.000 description 1
- BUVJSMCNKIHFCD-NSHDSACASA-N C[C@@H](C[n]1c2nc(-c3nc(Cl)ncc3C)c1)N(Cc1nc(C(F)F)ccc1)C2=O Chemical compound C[C@@H](C[n]1c2nc(-c3nc(Cl)ncc3C)c1)N(Cc1nc(C(F)F)ccc1)C2=O BUVJSMCNKIHFCD-NSHDSACASA-N 0.000 description 1
- DHPAIROIAXACNO-ZDUSSCGKSA-N Cc(c(-c1c[n](C[C@@H](COC)N(Cc(cc2)cc(F)c2F)C2=O)c2n1)n1)cnc1Cl Chemical compound Cc(c(-c1c[n](C[C@@H](COC)N(Cc(cc2)cc(F)c2F)C2=O)c2n1)n1)cnc1Cl DHPAIROIAXACNO-ZDUSSCGKSA-N 0.000 description 1
- DRPYDUUPNVEQCA-CYBMUJFWSA-N Cc(c(-c1c[n](C[C@H](COC)N(Cc2nc(C(F)F)ccc2)C2=O)c2n1)n1)cnc1Cl Chemical compound Cc(c(-c1c[n](C[C@H](COC)N(Cc2nc(C(F)F)ccc2)C2=O)c2n1)n1)cnc1Cl DRPYDUUPNVEQCA-CYBMUJFWSA-N 0.000 description 1
- LDWCHEJBPZNGIS-UHFFFAOYSA-N Cc(cn1)c(-c2c[n](CCNC3=O)c3n2)nc1Cl Chemical compound Cc(cn1)c(-c2c[n](CCNC3=O)c3n2)nc1Cl LDWCHEJBPZNGIS-UHFFFAOYSA-N 0.000 description 1
- HVIGNZUDBVLTLU-MRXNPFEDSA-N Cc1c(-c2c[n](C[C@H](COC)N(Cc(cc3)cc(F)c3F)C3=O)c3n2)nc(Nc2ccn[n]2C)nc1 Chemical compound Cc1c(-c2c[n](C[C@H](COC)N(Cc(cc3)cc(F)c3F)C3=O)c3n2)nc(Nc2ccn[n]2C)nc1 HVIGNZUDBVLTLU-MRXNPFEDSA-N 0.000 description 1
- KMPXZNPDWGUHKX-GOSISDBHSA-N Cc1c(-c2c[n](C[C@H](COC)N(Cc3cc(OC)ccc3)C3=O)c3n2)nc(Nc2ccn[n]2C)nc1 Chemical compound Cc1c(-c2c[n](C[C@H](COC)N(Cc3cc(OC)ccc3)C3=O)c3n2)nc(Nc2ccn[n]2C)nc1 KMPXZNPDWGUHKX-GOSISDBHSA-N 0.000 description 1
- CQNIYQCVDLBGPY-UHFFFAOYSA-N FC(c1ccnc(Cl)c1)F Chemical compound FC(c1ccnc(Cl)c1)F CQNIYQCVDLBGPY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252726P | 2015-11-09 | 2015-11-09 | |
| US201662401351P | 2016-09-29 | 2016-09-29 | |
| PCT/EP2016/076932 WO2017080979A1 (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2780650T3 true ES2780650T3 (es) | 2020-08-26 |
Family
ID=57241113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16791420T Active ES2780650T3 (es) | 2015-11-09 | 2016-11-08 | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer |
Country Status (35)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457669B2 (en) | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| WO2017080979A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| EP3845538B1 (en) * | 2018-10-10 | 2023-11-08 | Shenzhen TargetRx, Inc. | Dihydroimidazopyrazinone compound, composition including same, and use thereof |
| JP2022527744A (ja) | 2019-03-28 | 2022-06-06 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用 |
| JP2022534224A (ja) | 2019-05-24 | 2022-07-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用 |
| CN117486890A (zh) * | 2019-06-06 | 2024-02-02 | 和记黄埔医药（上海）有限公司 | 三环类化合物及其用途 |
| AU2020397222B2 (en) * | 2019-12-05 | 2023-07-06 | Astrazeneca Ab | Process and intermediates for the production of formula (i) |
| CA3160903A1 (en) * | 2019-12-06 | 2021-06-10 | Medshine Discovery Inc. | Thiazololactam compound as erk inhibitor and use thereof |
| JP2023543080A (ja) | 2020-09-29 | 2023-10-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ピロロ複素環系誘導体の結晶及びその製造方法 |
| AR126166A1 (es) * | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |
| WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
| AU2022320304A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2023081859A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
| US20250340572A1 (en) | 2022-04-27 | 2025-11-06 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| EP4522623A1 (en) | 2022-05-12 | 2025-03-19 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2024006971A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| AU2003278377A1 (en) * | 2002-11-06 | 2004-06-07 | Merck Sharp And Dohme Limited | Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| JP5178738B2 (ja) * | 2006-12-20 | 2013-04-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 新規なｊｎｋ阻害剤 |
| NZ610948A (en) * | 2010-12-22 | 2014-06-27 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| EP2906562B1 (en) * | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| JP2013166727A (ja) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロイミダゾピラジノン誘導体 |
| AR090220A1 (es) | 2012-03-01 | 2014-10-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| US9867833B2 (en) * | 2013-12-06 | 2018-01-16 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| CA2934679C (en) | 2013-12-30 | 2023-02-28 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| WO2015103137A1 (en) | 2013-12-30 | 2015-07-09 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| JP6723926B2 (ja) | 2014-04-09 | 2020-07-15 | ジェネンテック， インコーポレイテッド | 医薬の製造方法 |
| US10412619B2 (en) * | 2014-11-14 | 2019-09-10 | Qualcomm Incorporated | Buffer status report for eDCS |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| US10238657B2 (en) | 2015-06-03 | 2019-03-26 | Js Innopharm (Shanhai) Ltd. | Heterocyclic compounds for treating psoriasis |
| US10479791B2 (en) | 2015-06-03 | 2019-11-19 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as ERK inhibitors |
| WO2017080979A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
-
2016
- 2016-11-08 WO PCT/EP2016/076932 patent/WO2017080979A1/en not_active Ceased
- 2016-11-08 JP JP2018522784A patent/JP6877423B2/ja active Active
- 2016-11-08 LT LTEP16791420.9T patent/LT3374359T/lt unknown
- 2016-11-08 TN TNP/2018/000119A patent/TN2018000119A1/en unknown
- 2016-11-08 AU AU2016351813A patent/AU2016351813B2/en active Active
- 2016-11-08 SG SG11201803066VA patent/SG11201803066VA/en unknown
- 2016-11-08 MY MYPI2018000675A patent/MY197626A/en unknown
- 2016-11-08 CR CR20180316A patent/CR20180316A/es unknown
- 2016-11-08 CA CA3003549A patent/CA3003549A1/en active Pending
- 2016-11-08 HR HRP20200342TT patent/HRP20200342T1/hr unknown
- 2016-11-08 BR BR112018008397-6A patent/BR112018008397B1/pt active IP Right Grant
- 2016-11-08 MX MX2018005725A patent/MX376639B/es active IP Right Grant
- 2016-11-08 DK DK16791420.9T patent/DK3374359T3/da active
- 2016-11-08 SM SM20200152T patent/SMT202000152T1/it unknown
- 2016-11-08 SI SI201630668T patent/SI3374359T1/sl unknown
- 2016-11-08 EP EP16791420.9A patent/EP3374359B1/en active Active
- 2016-11-08 ES ES16791420T patent/ES2780650T3/es active Active
- 2016-11-08 KR KR1020187016091A patent/KR20180074788A/ko not_active Withdrawn
- 2016-11-08 TW TW105136236A patent/TWI730012B/zh not_active IP Right Cessation
- 2016-11-08 CN CN201680064567.2A patent/CN108349983B/zh active Active
- 2016-11-08 PE PE2018000611A patent/PE20181288A1/es unknown
- 2016-11-08 PT PT167914209T patent/PT3374359T/pt unknown
- 2016-11-08 ME MEP-2020-72A patent/ME03770B/me unknown
- 2016-11-08 PL PL16791420T patent/PL3374359T3/pl unknown
- 2016-11-08 EA EA201891063A patent/EA038028B1/ru unknown
- 2016-11-08 RS RS20200392A patent/RS60155B1/sr unknown
- 2016-11-08 US US15/345,537 patent/US9902731B2/en active Active
-
2018
- 2018-01-18 US US15/873,965 patent/US10202391B2/en active Active
- 2018-04-26 IL IL258953A patent/IL258953A/en active IP Right Grant
- 2018-05-03 NI NI201800058A patent/NI201800058A/es unknown
- 2018-05-07 PH PH12018500987A patent/PH12018500987A1/en unknown
- 2018-05-07 CL CL2018001226A patent/CL2018001226A1/es unknown
- 2018-05-07 SV SV2018005687A patent/SV2018005687A/es unknown
- 2018-05-07 CO CONC2018/0004857A patent/CO2018004857A2/es unknown
- 2018-06-06 ZA ZA2018/03742A patent/ZA201803742B/en unknown
-
2020
- 2020-04-02 CY CY20201100314T patent/CY1123627T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2780650T3 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| ES2907759T3 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina útiles en el tratamiento del cáncer | |
| ES2688553T3 (es) | Inhibidores de JAK1 para el tratamiento de síndromes mielodisplásicos | |
| AU2014208964B2 (en) | Chemical compounds | |
| EP4483881A2 (en) | Fused ring compounds | |
| WO2017080980A1 (en) | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer | |
| JP2020519589A (ja) | Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物 | |
| CN107108648A (zh) | 作为ERK抑制剂的噻吩并[2,3‑c]吡咯‑4‑酮衍生物 | |
| EP3596064B1 (en) | Tosylacetate based compounds and derivatives thereof as phgdh inhibitors | |
| KR20180052623A (ko) | 신규 화합물 | |
| WO2016162325A1 (en) | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors | |
| EA038233B1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| KR20180052631A (ko) | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 | |
| HK1256283B (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| HK40097417A (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| HK1214592B (en) | Chemical compounds |